76 related articles for article (PubMed ID: 38644266)
1. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
Ciruelos E; García-Sáenz JÁ; Gavilá J; Martín M; Rodríguez CA; Rodríguez-Lescure Á
Clin Transl Oncol; 2024 Jul; 26(7):1539-1548. PubMed ID: 38336982
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab deruxtecan in breast cancer.
Martín M; Pandiella A; Vargas-Castrillón E; Díaz-Rodríguez E; Iglesias-Hernangómez T; Martínez Cano C; Fernández-Cuesta I; Winkow E; Perelló MF
Crit Rev Oncol Hematol; 2024 Jun; 198():104355. PubMed ID: 38621469
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT; Meric-Bernstam F; Bardia A; Naito Y; Siena S; Aftimos P; Anderson I; Curigliano G; de Miguel M; Kalra M; Oh DY; Park JO; Postel-Vinay S; Rha SY; Satoh T; Spanggaard I; Michelini F; Smith A; Machado KK; Saura C;
Lancet Oncol; 2024 Jun; 25(6):707-719. PubMed ID: 38710187
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
Takahashi S; Bando H; Kinoshita I; Modi S; Tsurutani J; Bang YJ; Sato Y; Nakatani S; Lee C; Sugihara M; Okuda Y; Iwata H
Jpn J Clin Oncol; 2024 Apr; 54(4):434-443. PubMed ID: 38231777
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
[TBL] [Abstract][Full Text] [Related]
9. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
Ali A; Graff SL
Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
[TBL] [Abstract][Full Text] [Related]
10. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G; Dent R; Earle H; Modi S; Tarantino P; Viale G; Tolaney SM
ESMO Open; 2024 Apr; 9(4):102989. PubMed ID: 38613914
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone.
Pearson J; Khan A; Bhogal T; Wong H; Law A; Mills S; Santamaria N; Bishop J; Cliff J; Errington D; Hall A; Hart C; Malik Z; Sripadam R; Innes H; Flint H; Langton G; Ahmed E; Jackson R; Palmieri C
ESMO Open; 2023 Dec; 8(6):102033. PubMed ID: 37866031
[TBL] [Abstract][Full Text] [Related]
12. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY
Future Oncol; 2024 Apr; ():1-14. PubMed ID: 38592002
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan.
Neupane N; Thapa S; Bhattarai A; Ahuja K; Schlam I; Mittal A; Tolaney SM; Tarantino P
Curr Oncol Rep; 2023 Dec; 25(12):1467-1482. PubMed ID: 37938529
[TBL] [Abstract][Full Text] [Related]
14. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.
Cecco S; Puligheddu S; Fusaroli M; Gerratana L; Yan M; Zamagni C; De Ponti F; Raschi E
Target Oncol; 2024 May; 19(3):435-445. PubMed ID: 38696126
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38797792
[TBL] [Abstract][Full Text] [Related]
16. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
[TBL] [Abstract][Full Text] [Related]
17. Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer.
Liu J; Zhu T; Zhao R; Ren W; Zhao F; Liu J
Gastric Cancer; 2024 May; 27(3):495-505. PubMed ID: 38386239
[TBL] [Abstract][Full Text] [Related]
18. Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.
Morgovan C; Dobrea CM; Butuca A; Arseniu AM; Frum A; Rus LL; Chis AA; Juncan AM; Gligor FG; Georgescu C; Ghibu S; Vonica-Tincu AL
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790915
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Apr; ():. PubMed ID: 38648979
[TBL] [Abstract][Full Text] [Related]
20. [Chinese expert consensus statement on the classification and interpretation of variants in genes associated with common inherited cardiovascular diseases].
; ;
Zhonghua Xin Xue Guan Bing Za Zhi; 2024 Apr; 52(4):338-368. PubMed ID: 38644251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]